Early signs suggest that Alkermes might have found a therapeutic window with its IL-2-targeting agent, ALKS 4230.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
Almost in stealth mode the Swiss firm moves to begin a huge pivotal programme rivalling that of the IDO and IL-2 mechanisms.
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.